Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

This target price adjustment aligns with investors shifting their focus towards the third quarter results of the SURPASS-CVOT ...

In honor of Higher Education Day, celebrate FIU’s earning its latest Carnegie recognition — and meet recent alumni who are ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

A powerful and wealthy church member left Christ Church, calling its leader "a hippie." Church women united around strawberry ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

Buy low, sell high” is a common investing mantra. It’s easy to understand, but often hard to execute because emotion gets in the way. When great stocks are sale, things are often bleak.

Twenty years ago, back before iPhones, Instagram or Uber existed, Franklin College journalism students were facing a ...

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...